Close
4

Seqens Seqens

X

Company profile for SemaThera Inc

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
SemaThera develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). SEMA 3A is a soluble protein that promotes vascular leakage and contributes to diabetes-related macular edema. Its levels are significantly elevated in the vitreous of patients with DME as well as in several other vascular diseases of the retina. Importantly, SEMA 3A levels rise in the early stages o...
SemaThera develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). SEMA 3A is a soluble protein that promotes vascular leakage and contributes to diabetes-related macular edema. Its levels are significantly elevated in the vitreous of patients with DME as well as in several other vascular diseases of the retina. Importantly, SEMA 3A levels rise in the early stages of DME, while VEGF levels are still as low as in non-diabetic controls. Inhibiting SEMA 3A with SemaThera’s biological inhibitors has shown robust pre-clinical efficacy in preventing retinal vascular leakage, inflammation, apoptosis and pathological cytoskeleton remodelling.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
SemaThera Inc
Canada Flag
Country
Country
Canada
Address
Address
800-1 Westmount Square, Montreal, Québec Canada, H3Z 2P9
Telephone
Telephone
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY